logo

Last Update

This profile was last updated on 10/18/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Brett Houk?

Brett E. Houk

Director

Pfizer Inc

HQ Phone:  (212) 733-2323

Direct Phone: (858) ***-****direct phone

Email: b***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Pfizer Inc

235 East 42Nd Street

New York City, New York, 10017

United States

Company Description

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care produc...more

Find other employees at this company (68,028)

Web References(1 Total References)


ACKC e-Newsletter Volume 1 Number 1 | ACKC

Brett Houk, a Pfizer pharmacologist, presented the results of a retrospective study of the efficacy of sunitinib treatment in RCC and GIST patients for two dosing schedules, the standard 6-week cycle of 50 mg/day, 4 weeks on, 2 weeks off (4/2) versus continuous daily dosing (CDD) of 37.5 mg/day.
He reviewed the following trial data: for GIST, three Phase I-III Trials as follows: (a) 50 mg/day schedule 4/2 67 patients, (b) 50 mg/day schedule 4/2 211 patients (59 placebo), (c) 37.5 mg/day CDD 15 patients; for RCC, three Phase II Trials as follows: (a) 50 mg/day schedule 4/2 54 patients, (b) 50 mg/day schedule 4/2 92 patients, (c) 37.5 mg/day schedule CDD 51 patients; and one Phase III Trial 50 mg/day schedule 4/2 42 patients. Through his own and others analyses, Houk showed that for both RCC and GIST, sunitinib shows greater efficacy in patients with higher exposure in terms of time to progression, overall survival, and changes in tumor size. After reviewing the above trial data, Houk concluded that, for RCC and GIST, sunitnib is equally effective at the 37.5 mg/day continuous daily dosage as the 50 mg/day four weeks on two weeks off schedule. Unfortunately, he did not present data for the difference in adverse events between the two protocols.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory